Capped pyrazinoylguanidine sodium channel blockers

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C544S407000

Reexamination Certificate

active

11131262

ABSTRACT:
The present invention relates to a compound represented by formula (I):where the structural variables are as defined herein. The compound is useful for promoting hydration of mucosal surfaces.

REFERENCES:
patent: 4604394 (1986-08-01), Kaczorowski et al.
patent: 4894376 (1990-01-01), Morad et al.
patent: 6858614 (2005-02-01), Johnson
patent: 6858615 (2005-02-01), Johnson et al.
patent: 6903105 (2005-06-01), Johnson
patent: 2004/0198744 (2004-10-01), Johnson
patent: 2004/0198745 (2004-10-01), Johnson
patent: 2004/0198746 (2004-10-01), Johnson
patent: 2004/0198747 (2004-10-01), Johnson
patent: 2004/0198748 (2004-10-01), Johnson
patent: 2004/0198749 (2004-10-01), Johnson
patent: 2004/0204424 (2004-10-01), Johnson
patent: 2004/0204425 (2004-10-01), Johnson
patent: 2004/0229884 (2004-11-01), Johnson
patent: 2005/0059676 (2005-03-01), Johnson
patent: 2005/0080091 (2005-04-01), Johnson et al.
patent: 2005/0080092 (2005-04-01), Johnson
patent: 2005/0080093 (2005-04-01), Johnson et al.
patent: 2005/0090505 (2005-04-01), Johnson
patent: 2005/0113388 (2005-05-01), Johnson
patent: 2005/0113389 (2005-05-01), Johnson
patent: 2005/0113390 (2005-05-01), Johnson
patent: 1.525.670 (1968-04-01), None
patent: 1.525.671 (1968-04-01), None
Kellerman, “P2Y2 Receptor Agonists” Chest, vol. 121(5), supplement, pp. 201S-205S.(May 2002).
Cragoe, Jr., et al., Journal of Medicinal Chemistry, Jan. 1967, vol. 10, No. 1, pp. 66-75, “Pyrazine Diuretics. II. N-Amidino-3-amino-5-substituted 6-Halopyrazinecarboxamides”.
Kleyman, et al., American Journal of Physiology, 1991, vol. 260, Pt. 1, pp. C271-C276, “Distinct Epitopes on Amiloride. II Variably Restricted Epitopes Defined by Monoclonal Anti-Amiloride Antibodies”.
Cocks, et al., British Journal of Pharmacology, 1988, vol. 95, pp. 67-76, “Amiloride Analogues Cause Endothelium-Dependent Relaxation in the Canine Coronary Artery in Vitro: Possible Role of Na+/Ca2+Exchange”.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Capped pyrazinoylguanidine sodium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Capped pyrazinoylguanidine sodium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Capped pyrazinoylguanidine sodium channel blockers will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3750162

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.